Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study
Clinical Infectious Diseases · 08.01.2026 · 81 (Supplement_5) · S249-S255
DOI: 10.1093/cid/ciaf524 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 08.01.2026. Verfasst von Madeleine C Kline und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Gonorrhea, Anti-Bacterial Agents, Neisseria gonorrhoeae. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Background
Drug resistance in Neisseria gonorrhoeae is an urgent public health threat. The anticipated approval of 2 new antimicrobials for gonorrhea prompts the need for evidence-based rollout strategies that minimize drug resistance.
Methods
We used a stochastic compartmental model of men who have sex with men (MSM) in the United States (US) to compare 2 main strategies—equal allocation and sequential drug deployment—for 2 new and 1 existing drug and measured the time for each drug to reach a resistance prevalence threshold of 5%. We conducted broad analyses assessing the sensitivity of our results to wide variation in parameters governing the baseline behavior of the model and drug resistance evolution and fitness.
Results
Compared to the equal allocation strategy, the sequential strategy had reached the resistance prevalence threshold i) for each drug individually in at least as many simulations; ii) for all 3 drugs in at least as many simulations; and iii) for at least as many drugs on average. After 10 years, no equal allocation strategy simulations had met the 5% resistance prevalence threshold for any of the drugs, whereas 99.6% of sequential simulations had for the first drug, of which 3.5% had also met the threshold for the second drug. The sequential strategy was worse for nearly every reasonable combination of model parameters.
Conclusions
In a model of US MSM, the equal allocation strategy for introducing new drugs for gonorrhea matched or outperformed the strategy of sequential introduction in terms of resistance prevalence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
ORCID-Profile: Madeleine C Kline, Kirstin Oliveira Roster, David Helekal, Eva Rumpler, Yonatan H Grad
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIA NIH HHS
- U.S. Centers for Disease Control and Prevention
- NIH HHS
- CDC
- NIH
- National Institute of General Medical Sciences
Zitieren
APA
Kline, M. C., Oliveira Roster, K., Helekal, D., Rumpler, E., & Grad, Y. H. (2026). Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study. Clinical Infectious Diseases, 81(Supplement_5), S249-S255. https://doi.org/10.1093/cid/ciaf524
Vancouver
Kline MC, Oliveira Roster K, Helekal D, Rumpler E, Grad YH. Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study. Clinical Infectious Diseases. 2026;81(Supplement_5):S249-S255. doi:10.1093/cid/ciaf524
BibTeX
@article{Kline2026,
author = {Kline, Madeleine C and Oliveira Roster, Kirstin and Helekal, David and Rumpler, Eva and Grad, Yonatan H},
title = {Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {81},
number = {Supplement_5},
pages = {S249--S255},
doi = {10.1093/cid/ciaf524}
}
EUVIMED